Endocrine Society member Daniel J. Drucker, MD , and Jens Juul Holst, MD, DMSc, have been honored with the 2026 Lefoulon-Delalande Foundation Scientific Prize from the Institut de France for their work on GLP-1s, a key hormone in metabolic regulation.
Each year, the Lefoulon-Delalande Foundation awards its Scientific Prize to a scientist who has made a major contribution to cardiovascular physiology, biology, or medicine. In 2026, the Scientific Prize, endowed with €600,000, will be shared equally between two laureates and their laboratories.
The scientific council awarded the 2026 Lefoulon-Delalande Foundation Scientific Prize to the duo by majority decision. GLP-1 plays a crucial role in the regulation of metabolic balance, particularly in the control of blood glucose levels and in the pathophysiology of diseases such as type 2 diabetes, obesity, inflammation, and cardiovascular diseases.
The therapeutic development of GLP-1 agonists has had a major impact on the management of these conditions and, more broadly, on human health.
Endocrine News published a clinical update in Research Highlights on 19 May 2026.
The item focuses on Daniel J.
Drucker, MD, Receives the 2026 Lefoulon-Delalande Foundation Scientific Prize.
Review the original article for the full source wording and details.